Recruiting

iDose TR

Sponsor:

Glaukos Corporation

Code:

NCT07816692

Conditions

Open Angle Glaucoma (OAG)

Ocular Hypertension (OHT)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

iDose TR (travoprost intracameral implant) 75 µg

Study Details

Brief summary:

Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.

Conditions

Open Angle Glaucoma (OAG)

Ocular Hypertension (OHT)

Study ID

NCT07816692

Start date

May 13, 2026

Status verified date

Sep, 2026

Completion date

Mar, 2027

Anticipated

Primary completion date

Mar, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT)

Exclusion Criteria:

  • Prior administration of iDose TR or administration of an investigational intracameral implant in the study eye Active ocular infection or inflammation History of hypersensitivity to travoprost or implant components Recent ocular surgery Uncontrolled systemic disease Any condition preventing safe implantation

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Arms

iDose TR

Travoprost Intracameral Implant

Interventions

iDose TR (travoprost intracameral implant) 75 µg

Travoprost-releasing implant preloaded in a sterile, single-use inserter.

Primary outcome measure

  • Successful administration of iDose TR in an office-based surgical setting. [ Time Frame: 3 months ]

Central Contacts and Locations

Central contacts

Study Director

949-739-8749ClinicalResearch@glaukos.com

Locations

Glaukos Investigative Site

Recruiting

Austin, Texas, United States, 78746

Contacts

Glaukos Investigative Site

949-739-8749ClinicalResearch@glaukos.com

More Information

Sponsor

Glaukos Corporation

Last update posted

Sep 14, 2026

Last verified

Sep, 2026

Keywords

  • Glaucoma
  • Ocular Hypertension

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-15. This information was provided to ClinicalTrials.gov by Glaukos Corporation on 2026-09-14.